ProfileGDS5678 / 1423554_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 40% 41% 41% 45% 43% 38% 37% 41% 39% 41% 40% 41% 43% 45% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.9643240
GSM967853U87-EV human glioblastoma xenograft - Control 22.9413941
GSM967854U87-EV human glioblastoma xenograft - Control 32.9470341
GSM967855U87-EV human glioblastoma xenograft - Control 42.9970345
GSM967856U87-EV human glioblastoma xenograft - Control 52.9431943
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.957738
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9092937
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9231741
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8715839
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9272641
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9128440
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9204741
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0000543
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0516145